Please login to the form below
Zocor
This page shows the latest Zocor news and features for those working in and with pharma, biotech and healthcare.
FDA panel rejects cardiovascular outcomes claim for Vytorin
expire. Vytorin has been a somewhat controversial product for Merck since the publication of the ENHANCE trial, which compared the drug to simvastatin (Merck's now off-patent brand Zocor) alone
Latest news
-
Merck's ezetimibe has 'modest' benefit when added to statins
The IMPROVE-IT trial was designed to compare the effects of Vytorin (simvastatin and ezetimibe) versus Zocor (simvastatin) on cardiovascular complications and death in 18, 000 post-ACS patients and got ... to 34.7% of the Zocor group, a difference that
-
Clinical study potential for electronic health records
In the Retropro trial 300 patients with a high risk of cardiovascular disease were randomised between simvastatin (the generic form of MSD's Zocor) and atovastatin (the generic form of
-
Merck forges on with Vytorin trial after safety review
The IMPROVE-IT study is comparing Vytorin (simvastatin and ezetimibe) to Zocor (simvastatin) in 18, 000 patients and has been cleared to continue after an independent monitoring board concluded there were
-
Label update for simvastatin
myopathy. The updates will be made to the label of products containing the highest approved dose of simvastatin (80mg), including Zocor, marketed by Merck.
-
Abbott's Niaspan disappoints in trial
attacks and stroke, in certain patients already receiving Merck's Zocor (simvastatin).
More from news
Approximately 1 fully matching, plus 39 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
